Overview

A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102)

Status:
Completed

Trial end date:
2020-03-04

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and tolerability of pemigatinib in Japanese subjects with advanced malignancies.

Phase:

Phase 1

Details

Lead Sponsor:

Incyte Corporation